Hydromorphone Hydrochloride
FDA Label NDC 13811-720

55 label sections · Submitted to the FDA by Trigen Laboratories, Llc · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Trigen Laboratories, Llc for the product Hydromorphone Hydrochloride (NDC 13811-720). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: serious and life-threatening risks from use of hydromorphone hydrochloride extended-release tablets, 1 indications and usage, 2.1     important dosage and administration information, 2.2     patient access to an opioid overdose reversal agent for the emergency treatment of opioid overdose, 2.3     initial dosage, 2.4     titration and maintenance of therapy, 2.5     safe reduction or discontinuation of hydromorphone hydrochloride extended-release tablets, 2.6     dosage modifications in patients with moderate hepatic impairment, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

* Please review the disclaimer below.